Intravenous thrombolysis for ischemic stroke in extended time window selected with CT perfusion: a systematic review and meta-analysis.

J Stroke Cerebrovasc DisJul 31, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Marcello Naccarato, Edoardo Ricci, Emanuele Vincis et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS) treated within an extended time window (ETW) using CT perfusion imaging. The analysis included six randomized controlled trials with 1182 patients receiving IVT and 1176 receiving best medical treatment. IVT was associated with improved functional outcomes at 3 months, despite an increased risk of symptomatic intracranial hemorrhage.

Key findings

  • IVT was linked to a higher likelihood of achieving excellent functional outcomes at 3 months.
  • Patients receiving IVT had a greater chance of good functional outcomes compared to those receiving BMT.
  • No significant difference in 90-day mortality was found between IVT and BMT groups.
  • IVT was associated with an increased risk of symptomatic intracranial hemorrhage.

Why it matters

Understanding the benefits and risks of IVT in the extended time window is crucial for clinicians managing acute ischemic stroke, as it may influence treatment decisions and patient outcomes.

Source

PubMed · PMID 42537729

Published in J Stroke Cerebrovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.